Executive Briefing - Getting to grips with advanced therapies in the EU
This article was originally published in Scrip
It is now almost a year since new EU rules on the development, evaluation and approval of advanced therapies came into effect. Ian Schofield assesses progress so far and looks at which kinds of products are likely to be coming through the system over the next few years.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.